fashion -WSS

fashion

author：entertainment 2025-09-28 23:48:01 - browse：8512

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： As H5N1 spreads in cows, experts warn against drinking raw milk

WSS

Friends ask where James Watson's attitudes about race came from

Supreme Court to hear if Covid misinformation is protected speech

American woman, child freed after being kidnapped in Haiti last month

Wegovy trial has doctors encouraged over new possibilities

NIH trials fail to test meaningful long Covid therapies, experts say

Maui's cultural, historic landmarks damaged in the devastating wildfires

Wikipedia

fashion

hotspot

Activists slam private health insurers over coverage restrictions

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Novavax promises a turnaround & Lilly roils the obesity market

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

The cancer drug shortage isn’t new — and neither are the solutions

Abbott's new stent may help patients with peripheral artery disease

Duchenne breakthrough therapy leaves behind pioneering families

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

How one medical school became remarkably diverse

Methadone doses haven’t kept up in the age of fentanyl

focus

Fertility clinic egg and embryo storage is a disaster

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Drastic changes should bring profitability, startup health insurers say

How to use technology to prevent future drug shortages

South Korea throws huge K

Maui's cultural, historic landmarks damaged in the devastating wildfires

entertainment

Wikipedia

leisure time

focus